26th May 2015 07:10
LONDON (Alliance News) - Shares in Eden Research PLC were trading up 21% Tuesday morning after it announced that its first product 3AEY has been authorised for the treatment of botrytis in table and wine grapes from the Regulatory Affairs Directorate in Malta.
Malta is acting as the zonal rapporteur member state for the Southern EU agricultural zone. Following this authorisation Eden expects the remaining member states across the Southern Zone to grant authorisation for the sale and use of 3AEY in their jurisdictions within the allocated 120 days.
"As our licensees, partners and shareholders well know, we have been pursuing the authorisation to sell 3AEY in the EU Southern Zone for nearly eight years. This is not only excellent news for our licensees, but also for Eden," said Chief Executive Officer Sean Smith in a statement.
Shares in Eden Research are trading up 21% at 14.50 pence Tuesday morning, one of the best performers in the AIM All-Share.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Eden